This segment focuses on the research and development of novel therapeutics for chronic hepatitis B (CHB), a significant global health challenge. Aligos is developing multiple drug candidates, including ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer currently in Phase Ib clinical trials, and ALG-000184, a capsid assembly modulator in Phase I trials. Research and development activities include preclinical studies, clinical trial management, and formulation development. The company utilizes oligonucleotide polymer and capsid assembly modulator technologies. The goal is to provide effective and safe treatments to improve patient outcomes and potentially achieve a functional cure for CHB. Market positioning involves targeting a large patient population with high unmet medical needs. Future opportunities include expanding the pipeline with additional CHB therapies and seeking regulatory approvals. Partnerships with Luxna Biotech Co., Ltd. support the development and commercialization of oligonucleotide-based products.

This segment is dedicated to developing treatments for non-alcoholic steatohepatitis (NASH), a progressive liver disease with limited therapeutic options. Aligos is developing ALG-055009, a small molecule THR-β agonist, currently in Phase 1a/1b clinical trials. Research and development efforts include preclinical studies, clinical trial management, and formulation development. The company leverages small molecule drug discovery and development. The aim is to address the growing prevalence of NASH and improve patient outcomes by reducing liver inflammation and fibrosis. Market positioning involves targeting a large and growing patient population with high unmet medical needs. Future opportunities include expanding the NASH pipeline and seeking regulatory approvals. The company has a collaboration with Merck to discover, research, optimize, and develop oligonucleotides directed against NASH.